Skip to main content

Myriad Genetics Inc (MYGN)

Sector
Biotechnology
Last price
$5.54
As of

Kresmion compiles this page from MYGN's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.

MYRIAD GENETICS INC (MYGN): 1 institutional manager tracked by Kresmion reported non-option positions in their 2026Q3 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-11-09.

As of . Source: SEC EDGAR filings for MYGN. Method and limitations.

COMPANY DOSSIER

See the full MYGN dossier

Price with insider and filing markers, who is positioning, fundamentals and peers for MYGN on one page. Preview it with sample data, then open it live with a free account.

Preview the MYGN dossier

Active events for MYGN

FREE, NO ACCOUNT

Every event on MYGN, as it fires

You are seeing 5 of 11 events recorded on MYGN since 2026-06-02.

The five above landed across 2 days. The other 6 were recorded on 3 other days.

Get it by email

No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.

Join on Telegram
Join on Telegram

One tap. Live alerts, no email needed.

MYGN positions held by the managers we follow (2026Q3)

What the managers we follow bought and sold in Q2 2026

Manager / securityMarket value% of reported value
RENAISSANCE TECHNOLOGIES LLC FundCUSIP 62855J104 · 2026Q3$1.1M0.00%

Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. The share of reported value is each position's value over the sum of the values that manager reported for the quarter; option lines are not in that sum, as on each fund page. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.

Recent SEC filings, MYGN

More data on MYGN

MYGN against its peers

MYGN's operating margin of -47.0% ranks in the 88th percentile of 12 Biotechnology sub-industry peers, fiscal period ending 2025-12-31.

MetricMYGNPeer medianPercentilen
Revenue FY825M USD7.3M USD9715
Gross margin69.9%n/an/a3
Operating margin-47.0%-387.5%8812
Net margin-44.4%-239.0%8112
Return on equity-99.4%-47.0%2021
1 year-13.5%5.5%2521

Peers (22): ZVRA, VALN, CAPR, EPRX, CBIO, SANA, ENTX, FTH, OBIO, SRZN, RGNX, NGNE, MNPR, GERN, CLYM, OVID, CGEM, ABUS, DMAC, STTK, WVE, GYRE. Left out: SLBT (no annual filing), IAM (no annual filing), ETRA (no annual filing). Fiscal period ending 2025-12-31. Every figure is one full fiscal year read from one annual filing (MYGN: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.

Related tickers

Cite this data

Kresmion counts the managers it follows that reported a non-option position in MYGN on Form 13F-HR for the latest reporting quarter, orders those positions by the value each filing reports, and lists the company's latest SEC filings and the events Kresmion recorded on MYGN in the last 180 days.

Upstream: SEC EDGAR filings for MYGN

Kresmion, "MYRIAD GENETICS INC (MYGN) institutional holdings and SEC filings", data as of 2026-11-16, https://kresmion.com/research/MYGN. Upstream data: SEC EDGAR filings for MYGN.

Link to this data (HTML):

<a href="https://kresmion.com/research/MYGN">MYRIAD GENETICS INC (MYGN) institutional holdings and SEC filings (Kresmion)</a>

Writing about this? Press contact and ready-to-quote figures

Follow MYGN on a live board

Kresmion is a source-first market terminal for cross-asset market intelligence. Open a board scoped to MYGN for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.

Preview the MYGN dossier
Share

The MYGN intelligence card: the smart money composite, cross family confluence and the top current signal, with a link back to this page.